Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014087
Chunk: 18

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 18
---
000 |
|                                          |   | December 31, 2024 |     |   |         |     |   |           |     |   |           |
|                                          |   |           Level 1 |     |   | Level 2 |     |   |   Level 3 |     |   |     Total |
| Current assets:                          |   |                   |     |   |         |     |   |           |     |   |           |
| Money market funds                       | $ |         4,164,323 |     | $ | -       |     | $ |         - |     | $ | 4,164,323 |
| Total assets measured at fair value      | $ |         4,164,323 |     | $ | -       |     | $ |         - |     | $ | 4,164,323 |

The Company's cash equivalents are classified as Level 1. The fair value of the Company's cash and cash equivalents is determined based on market pricing that is both objective and publicly available. The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented. As of June 30, 2025 and December 31, 2024, the carrying amounts of the Company's other financial instruments, which include cash, accounts payable, and accrued expenses, approximate fair values because of their short-term maturities.

15

10. Commitment and contingencies

Commitments

As of June 30, 2025, the Company had no long-term commitments.

Contingencies

In the ordinary course of business, from time to time, the Company may be involved in various claims related to operations, rights, commercial, employment or other claims. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to such claims to be material to these consolidated financial statements.

11. Segment reporting

The Company manages the business activities on a consolidated basis and operates as one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company's product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company's CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. The significant segment expense categories (general and administrative and research and